Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia.
Autor: | Faber, J., Vos, P., Kegler, D., van Norren, K., Argilés, J. M., Laviano, A., Garssen, J., van Helvoort, A., Argilés, J M |
---|---|
Předmět: |
CACHEXIA treatment
IMMUNOREGULATION OLIGOSACCHARIDES LEUCINE CANCER patient psychology CYTOKINES FISH oils MICE physiology LABORATORY mice THERAPEUTICS LIPOPOLYSACCHARIDES BIOLOGICAL models DINOPROSTONE CELL physiology PLANT proteins FOOD TUMORS CACHEXIA SPLEEN CELL lines T cells MICE ANIMALS DISEASE complications |
Zdroj: | British Journal of Cancer; 12/16/2008, Vol. 99 Issue 12, p2029-2036, 8p, 3 Charts, 3 Graphs |
Abstrakt: | The majority of patients with advanced cancer are recognised by impaired immune competence influenced by several factors, including the type and stage of the tumour and the presence of cachexia. Recently, a specific nutritional combination containing fish oil, specific oligosaccharide mixture, high protein content and leucine has been developed aimed to support the immune system of cancer patients in order to reduce the frequency and severity of (infectious) complications. In a recently modified animal model cachexia is induced by inoculation of C26 tumour cells in mice. In a pre-cachectic state, no effect was observed on contact hypersensitivity, a validated in vivo method to measure Th1-mediated immune function, after adding the individual nutritional ingredients to the diet of tumour-bearing mice. However, the complete mixture resulted in significantly improved Th1 immunity. Moreover, in a cachectic state, the complete mixture reduced plasma levels of pro-inflammatory cytokines and beneficially affected ex vivo immune function. Accordingly, the combination of the nutritional ingredients is required to obtain a synergistic effect, leading to a reduced inflammatory state and improved immune competence. From this, it can be concluded that the specific nutritional combination has potential as immune-supporting nutritional intervention to reduce the risk of (infectious) complications in cancer patients. [ABSTRACT FROM AUTHOR] |
Databáze: | Complementary Index |
Externí odkaz: |